Stock GRANULES GRANULES INDIA LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Granules India Limited NSE India S.E.

Equities

GRANULES

INE101D01020

Market Closed - NSE India S.E.
Other stock markets
 07:43:48 2024-05-03 am EDT 		5-day change 1st Jan Change
423.4 INR -0.31% Intraday chart for Granules India Limited +1.29% +4.41%
Apr. 30 Granules Pharmaceuticals Arm Gets US FDA's Approval for Generic Drug for Gout Flares MT
Apr. 15 Granules India Gets Zero Observation from US FDA After Inspection of Visakhapatnam, India Unit MT

Strengths

  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • Analyst opinion has improved significantly over the past four months.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

  • With a 2024 P/E ratio at 24.97 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The company is highly valued given the cash flows generated by its activity.
  • The company is not the most generous with respect to shareholders' compensation.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
GRANULES INDIA LIMITED Stock Granules India Limited
+4.41% 1.23B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.08% 681B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+21.85% 556B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.77% 361B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.97% 325B
B-
ABBVIE INC. Stock AbbVie Inc.
+5.69% 285B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.68% 235B
B+
NOVARTIS AG Stock Novartis AG
+3.65% 199B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-11.12% 189B
A+
PFIZER, INC. Stock Pfizer, Inc.
-3.40% 157B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. GRANULES Stock
  4. GRANULES Stock
  5. Ratings Granules India Limited